FDA updates for February include a longer treatment duration for Izervay, a new tablet formulation for Evrysdi and approval of Gomekli, a MEK inhibitor to treat the rare genetic disorder neurofibromatosis. FDA also cleared Onapgo in Parkinson’s disease OFF episodes, Emblaveo for complicated intra-abdominal infections and Miudella, a low-dose copper-containing IUD. Ospomyv, Xbryk and Merilog are the latest biosimilars, plus Penmenvy is a pentavalent meningococcal vaccine, and Romvimza and Ctexli are approved in rare diseases.